It is very uncertain whether favipiravir changes all‐cause mortality – at 28 to 30 days, or in‐hospital compared with no treatment, supportive treatment, or other antiviral treatment (very low certainty).
It is very uncertain whether favipiravir changes progression to invasive mechanical ventilation compared with no treatment, supportive treatment, or other antiviral treatment (very low certainty).
Favipiravir showed no clear difference in need for admission to hospital (if ambulatory) compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
It is very uncertain whether favipiravir changes time to clinical improvement (defined as time to a 2‐point reduction… compared with no treatment, supportive treatment, or other antiviral treatment (very low certainty).
Favipiravir showed no clear difference in progression to oxygen therapy compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
Favipiravir may leads to higher all adverse events compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
Favipiravir showed no clear difference in serious adverse events attributable to the drug compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).